Answers are grounded in this paper and cite their sources.
Danish drugmaker Novo Nordisk plans to invest $220 million in a plant in Køge, Denmark, to produce raw materials for the company's therapies for chronic diseases. The 8,000 m 2 facility will include production and laboratory space. Novo expects the unit to be functional in 2027 and says it will create 50 new jobs. Last year, the company earmarked $6 billion to expand its existing manufacturing facilities in Kalundborg, Denmark, because of the demand for its antidiabetes and weight-loss medicines.
No takes yet. Share an insight, caveat, or question.
Aayushi Pratap (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: